Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt

Matei, Deliu Victor; Renne, Giuseppe; Pimentel, Marcelo; Sandri, Maria Teresa; Zorzino, Laura; Botteri, Edoardo; Cicco, Concetta De; Musi, Gennaro; Brescia, Antonio; Mazzoleni, Federica; Tringali, V.; Detti, Serena; Cobelli, Ottavio De

doi:10.1016/j.clgc.2011.12.004

Cited by 46 publications

(39 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the frequency of AR loss was not shown in the Japanese series. Matei et al (21) previously reported that the AR was positive in neoplastic cells in 20/47 patients (53%) with CRPC. Therefore, 47% of CRPC cases lost AR expression, which is higher compared to our series.…”

Section: Hspc Crpc --------------------------------------------------mentioning

confidence: 99%

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

Komiya

Yasuda

Watanabe

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Prostate cancer (PCa) is a leading cause of mortality, and despite good response to androgen ablation this response is eventually lost. In the present study, androgen receptor (AR) expression and neuroendocrine differentiation (NED) were evaluated in hormone-sensitive (HSPC) and castration-resistant prostate cancers (CRPC). Prostate tissues were obtained from 20 HSPC patients at diagnosis and 28 CRPC patients at castration-resistant progression. AR, chromogranin A (CGA) and neuron-specific enolase (NSE) were evaluated by immunohistochemical staining (IHS) in representative positive cores for PCa. IHS intensity was graded as negative, 0; positive, 1+ and strongly positive, 2+. The proportion of the 1+ and 2+ areas in PCa cells was determined. PCa was considered to be in NED if ≥50% of the tumor cells were 1+ or 2+ for CGA or NSE. The observed IHS intensity (0/1+/2+) for AR, CGA and NSE was 0/4/16, 5/11/4 and 11/4/5 in HSPC patients and 9/3/16, 5/8/15

show abstract

Section: Hspc Crpc --------------------------------------------------mentioning

confidence: 99%

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

Komiya

Yasuda

Watanabe

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…CgA appears to be the most sensitive marker and is most frequently used for detecting neuroendocrine differentiation either at the tissue level or in the general circulation. The availability of such a specific circulating marker for the neuroendocrine component could allow us to easily detect and monitor neuroendocrine differentiation in prostate cancer patients (Berruti et al 2005, Sciarra et al 2009, Matei et al 2012.…”

Section: Introductionmentioning

confidence: 99%

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Burgio

Conteduca

Menna

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

In this retrospective study, we evaluated the chromogranin A (CgA) baseline value as a predictor of clinical outcome in patients with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone 1000 mg per day, whose disease progressed after docetaxel chemotherapy. In the 48 evaluable patients, serum CgA level was normal when !120 ng/ml (group A, nZ16), within three times the upper normal value (UNV) when between 120 and 360 (group B, nZ16), more than three times the UNV when R360 ng/ml (group C, nZ16). Decline in PSA level R50% or more (PSA RR) was observed in 26 of 48 (54%) patients. PSA response rate did not correlate with the CgA groups. CgA levels more than three times the UNV predicted an early radiological progressive disease in eight of 11 cases (73%). The median progression-free survival (PFS) among the CgA groups A, B, and C was 9.2, 9.2, and 4.8 months respectively, PZ0.0459. The median overall survival (OS) among the CgA groups was 19.0, 18.8, and 10.8 months respectively, PZ0.2092. In the multivariate analysis, PSA RR (nonresponsive vs responsive) and CgA levels (group 3 vs groups 1C2) were predictors of PFS (PZ0.0002 and PZ0.0047 respectively), whereas PSA RR only was significantly associated with OS (PZ0.0024), while CgA levels remained of borderline significance (PZ0.0919). A serum CGA level more than three times the UNV predicted PFS and showed a trend vs OS prediction, independently from PSA response, in CRPC patients treated with abiraterone.

show abstract

“…La presencia de SSRT en el CP se relaciona con un fenó-meno llamado diferenciación neuroendocrina, que indica un pronóstico adverso. Se ha postulado en el adenocarcinoma de próstata la presencia de un incremento en el número de células neuroendocrinas, que no expresan receptores de andrógenos; por lo tanto, son andrógeno-independientes, de manera que establecen redes autocrinas y paracrinas para regular el crecimiento y la diferenciación, independientemente del estímulo androgénico 55 . No son muchos los reportes actuales que demuestran en un gran número de pacientes la utilidad de este radiotrazador en este poco frecuente proceso.…”

Section: Ga-dotatoc/nocunclassified

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

García-Pérez¹,

Medina-Ornelas²

2022

GAMO

View full text Add to dashboard Cite

Resumen El cáncer de próstata (CP) es la causa más común de cáncer en hombres a nivel mundial. Actualmente, la imagen en el CP ha tomado una gran importancia para la estadificación, reestadificación, selección del tratamiento y evaluación de la recurrencia. La imagen molecular con tomografía por emisión de positrones (PET) ha permitido un enfoque personalizado para estos propósitos. Además de estas necesidades clínicas, existe una creciente visión y reto para las nuevas técnicas de imagen molecular, no sólo para detectar la enfermedad metastásica, sino también para proporcionar información importante acerca de la biología tumoral, el pronóstico y, uno de los retos más grandes de las técnicas de imagen no radioisotópicas, la detección de recurrencia en pacientes con niveles bajos de antígeno prostático específico (APE). (creativecommons.org/licenses/by-nc-nd/4.0/). ARTÍCULO DE REVISIÓNRadiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

show abstract

Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt

Cited by 46 publications

References 49 publications

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

Contact Info

Product

Resources

About